Home > Cardiology > ESC 2020 > Late-Breaking Science > SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

Presented By
Prof. Francesco Cosentino, Karolinska University Hospital, Sweden
Conference
ESC 2020
Trial
VERTIS CV
In the VERTIS CV trial, SGLT2 inhibitor ertugliflozin did not meet the primary endpoint but did reduce the risk for first heart failure (HF) hospitalisations compared with placebo in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) with or without a history of HF [1]. These findings are consistent with results for other SGLT2 inhibitors. No fewer than 6 recent cardiovascular outcomes trials in patients with T2DM have consistently found a significant reduction in risk of HF hospitalisations with SGLT2 inhibitors [1]. Recent guidelines from the ESC and other scientific societies recommend the use of SGLT2 inhibitors in patients with T2DM to reduce the risk of HF hospitalisations events. VERTIS CV was a multicentre, randomised, placebo-controlled, event-driven trial including 8,246 patients with T2DM and established ASCVD. Of the p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on